The case for gnmt as a biomarker and a therapeutic target in pancreatic cancer
Biomarker, GNMT, 1, 2, 3, 4, 6-penta-O-galloyl-β-D-glucopyranoside, Pancreatic cancer
The high mortality rate for pancreatic cancer (PC) is due to the lack of specific symptoms at early tumor stages and a high biological aggressiveness. Reliable biomarkers and new therapeutic targets would help to improve outlook in PC. In this study, we analyzed the expression of GNMT in a panel of pancreatic cancer cell lines and in early-stage paired patient tissue samples (normal and diseased) by quantitative reverse transcription-PCR (qRT-PCR). We also investigated the effect of 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranoside (PGG) as a therapeutic agent for PC. We find that GNMT is markedly downregulated (p < 0.05), in a majority of PC cell lines. Similar results are observed in early-stage patient tissue samples, where GNMT expression can be reduced by a 100-fold or more. We also show that PGG is a strong inhibitor of PC cell proliferation, with an IC50 value of 12 ng/mL, and PGG upregulates GNMT expression in a dose-dependent manner. In conclusion, our data show that GNMT has promise as a biomarker and as a therapeutic target for PC.
Department of Biology
Original Publication Date
DOI of published version
UNI ScholarWorks, Rod Library, University of Northern Iowa
Heinzman, Zachary; Schmidt, Connor; Sliwinski, Marek K.; and Goonesekere, Nalin C.W., "The case for gnmt as a biomarker and a therapeutic target in pancreatic cancer" (2021). Faculty Publications. 102.